Foghorn Therapeutics Inc. (FHTX)

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTX

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc. - FHTX

Foghorn Therapeutics Pivots Pipeline after Ending Eli Lilly Deal

Foghorn to Slash 40% of Jobs as Lilly Cancer Partnership Falls Apart

Foghorn Therapeutics Provides Update on FHD-909 and Strategic Priorities

Wall Street Analysts Think Foghorn Therapeutics (FHTX) Could Surge 67.01%: Read This Before Placing a Bet

Here's Why Foghorn Therapeutics Inc. (FHTX) is a Great Momentum Stock to Buy

Wall Street Analysts Believe Foghorn Therapeutics (FHTX) Could Rally 88.47%: Here's is How to Trade

Foghorn Therapeutics Inc. (FHTX) Reports Q2 Loss, Beats Revenue Estimates

Foghorn Therapeutics Provides Second Quarter 2026 Financial and Corporate Update

Reviewing Foghorn Therapeutics (NASDAQ:FHTX) and Sunshine Biopharma (NASDAQ:SBFM)